MaaT Pharma (EURONEXT: MAAT – the “Company”), a French clinical-stage biotechnology company pioneering the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving the survival of cancer patients, today announces the participation of members of the management committee and the scientific team in several investor and scientific conferences scheduled for November:
– November 8-10, 2022: 9th edition of the International Human Microbiome Consortium (IHMC) congress
– November 9-11, 2022: 21st congress of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) – stand n°10
– November 14, 2022 – 7th annual Inve€$tival Showcase – LSX Leaders in partnership with Jefferies
– November 29, 2022 – Invest Day
To receive all of MaaT Pharma’s financial information in real time and for any questions, you can contact us via the following address: [email protected]